199 related articles for article (PubMed ID: 25240616)
41. Cytotoxicity, molecular modeling, cell cycle arrest, and apoptotic induction induced by novel tetrahydro-[1,2,4]triazolo[3,4-a]isoquinoline chalcones.
Mohamed MF; Hassaneen HM; Abdelhamid IA
Eur J Med Chem; 2018 Jan; 143():532-541. PubMed ID: 29207336
[TBL] [Abstract][Full Text] [Related]
42. Syntheses of novel β-carboline derivatives and the activities against five tumor-cell lines.
Bai B; Li XY; Liu L; Li Y; Zhu HJ
Bioorg Med Chem Lett; 2014 Jan; 24(1):96-8. PubMed ID: 24345445
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity.
Pingaew R; Mandi P; Nantasenamat C; Prachayasittikul S; Ruchirawat S; Prachayasittikul V
Eur J Med Chem; 2014 Jun; 81():192-203. PubMed ID: 24836071
[TBL] [Abstract][Full Text] [Related]
44. Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
Zhou W; Huang A; Zhang Y; Lin Q; Guo W; You Z; Yi Z; Liu M; Chen Y
Eur J Med Chem; 2015; 96():269-80. PubMed ID: 25899332
[TBL] [Abstract][Full Text] [Related]
45. Optimization of 2-(3-(arylalkyl amino carbonyl) phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone derivatives as potent antitumor growth and metastasis agents.
Wu J; Yu L; Yang F; Li J; Wang P; Zhou W; Qin L; Li Y; Luo J; Yi Z; Liu M; Chen Y
Eur J Med Chem; 2014 Jun; 80():340-51. PubMed ID: 24794770
[TBL] [Abstract][Full Text] [Related]
46. Bis-arylidene oxindoles as anti-breast-cancer agents acting via the estrogen receptor.
Pal A; Ganguly A; Ghosh A; Yousuf M; Rathore B; Banerjee R; Adhikari S
ChemMedChem; 2014 Apr; 9(4):727-32. PubMed ID: 24482362
[TBL] [Abstract][Full Text] [Related]
47. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues.
Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX
Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives.
Lan P; Wang J; Zhang DM; Shu C; Cao HH; Sun PH; Wu XM; Ye WC; Chen WM
Eur J Med Chem; 2011 Jun; 46(6):2490-502. PubMed ID: 21496972
[TBL] [Abstract][Full Text] [Related]
50. Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer.
Liu G; Yin T; Kim H; Ding C; Yu Z; Wang H; Chen H; Yan R; Wold EA; Zou H; Liu X; Ding Y; Shen Q; Zhou J
Eur J Med Chem; 2019 Sep; 178():589-605. PubMed ID: 31220676
[TBL] [Abstract][Full Text] [Related]
51. Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.
Qamar S; Carrasquer CA; Cunningham SL; Cunningham AR
Anticancer Res; 2011 Oct; 31(10):3247-52. PubMed ID: 21965732
[TBL] [Abstract][Full Text] [Related]
52. [Synthesis and structure-activity relationship of N-(2-arylethyl) isoquinoline derivatives as anti-cancer agents].
Wang YX; Zhao WL; Bi CW; Li YB; Shao RG; Song DQ
Yao Xue Xue Bao; 2012 Feb; 47(2):200-5. PubMed ID: 22512031
[TBL] [Abstract][Full Text] [Related]
53. Synthesis of novel building blocks of benzosuberone bearing coumarin moieties and their evaluation as potential anticancer agents.
Yadagiri B; Holagunda UD; Bantu R; Nagarapu L; Kumar CG; Pombala S; Sridhar B
Eur J Med Chem; 2014 May; 79():260-5. PubMed ID: 24742385
[TBL] [Abstract][Full Text] [Related]
54. Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer.
Akama T; Shida Y; Sugaya T; Ishida H; Gomi K; Kasai M
J Med Chem; 1996 Aug; 39(18):3461-9. PubMed ID: 8784443
[TBL] [Abstract][Full Text] [Related]
55. Discovery of N-substituted 3-arylisoquinolone derivatives as antitumor agents originating from O-substituted 3-arylisoquinolines via [2,3] or [3,3] rearrangement.
Li B; Wang G; Xu Z; Zhang Y; Huang X; Zeng B; Chen K; Shi J; Wang H; Zhu W
Eur J Med Chem; 2014 Apr; 77():204-10. PubMed ID: 24637214
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and cytotoxic activity of non-naturally substituted 4-oxycoumarin derivatives.
Serra S; Chicca A; Delogu G; Vázquez-Rodríguez S; Santana L; Uriarte E; Casu L; Gertsch J
Bioorg Med Chem Lett; 2012 Sep; 22(18):5791-4. PubMed ID: 22901895
[TBL] [Abstract][Full Text] [Related]
57. Design and synthesis of potent antitumor 5,4'-diaminoflavone derivatives based on metabolic considerations.
Akama T; Ishida H; Shida Y; Kimura U; Gomi K; Saito H; Fuse E; Kobayashi S; Yoda N; Kasai M
J Med Chem; 1997 Jun; 40(12):1894-900. PubMed ID: 9191967
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and antiproliferative activity of 4-substituted-piperazine-1-carbodithioate derivatives of 2,4-diaminoquinazoline.
Cao SL; Han Y; Yuan CZ; Wang Y; Xiahou ZK; Liao J; Gao RT; Mao BB; Zhao BL; Li ZF; Xu X
Eur J Med Chem; 2013 Jun; 64():401-9. PubMed ID: 23665106
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells.
Dandawate P; Khan E; Padhye S; Gaba H; Sinha S; Deshpande J; Venkateswara Swamy K; Khetmalas M; Ahmad A; Sarkar FH
Bioorg Med Chem Lett; 2012 May; 22(9):3104-8. PubMed ID: 22483392
[TBL] [Abstract][Full Text] [Related]
60. Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents.
Duan YC; Ma YC; Zhang E; Shi XJ; Wang MM; Ye XW; Liu HM
Eur J Med Chem; 2013 Apr; 62():11-9. PubMed ID: 23353743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
